|
|
La Jolla Pharmaceutical Company - Price Analysis Snapshot
This Report features up to a ten-year record of the equity Price history for La Jolla Pharmaceutical Company. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.
La Jolla Pharmaceutical Company. The Group's principal activity is to conduct research and development of therapeutics for the treatment of certain life-threatening antibody-mediated diseases. The diseases include autoimmune conditions such as systemic lupus erythematosus and antibody-mediated stroke that are caused by abnormal B cell production of antibodies that attach healthy tissues. The current therapies for these autoimmune disorders target the symptoms of the diseases or nonspecifically suppress the normal operation of the immune system. The Group's strategy is to Collaborate with pharmaceutical companies to access their research, drug development, manufacturing, marketing and financial resources. On January 11, 2006, The Group announced that would initiate a multi-dose clinical study of Riquent in lupus patients to evaluate the ability of higher doses of Riquent to further reduce antibodies to double stranded DNA.
Not the Report you are looking for? Click here for more browsing options.
Layout and Content of a Typical Report
|
|
|
|
|